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ELEVATED ORAL CLEARANCE OF VERAPAMIL IN
CYP3A5 EXPRESSERS. Y. Jin, MD, Y. Wang, PhD, M. A. Ham-
man, MS, R. Marunde, BS, Z. Hu, MD, PhD, J. Hilligoss, S. D. Hall,
PhD, Indiana University, Indianapolis, IN.
BACKGROUND/AIMS: Verapamil, a CYP3A4 substrate and
inhibitor in vivo, is a more potent mechanistic inhibitor of CYP3A4
than CYP3A5 in vitro. We hypothesized that the clearance of vera-
pamil would be different in subjects genetically capable of expressing
CYP3A5 compared to non-expressers.
METHODS: Twenty healthy subjects with predetermined
CYP3A5 genotype were recruited. CYP3A5 3, 6 and 7 genotypes
were determined with real-time PCR. After an outpatient course of
verapamil 240 mg per day for 7 days, verapamil pharmacokinetics
were determined on days 8 and 9. Serum concentrations of R- and S-
verapamil and R- and S-norverapamil were determined with by chiral
LC/MS. Verapamil pharmacokinetics parameters were derived from
non-compartmental analysis (WinNonlin). Differences in the phar-
macokinetic parameters among subjects with different CYP3A5 ge-
notypes were tested with Student’s t tests (SPSS v12).
RESULTS: CYP3A5 expressers (subjects with at least one 1
allele) had a statistically higher orally clearance for R and S vera-
pamil (table 1). There is a trend towards lower R- and S- verapamil
Cmax in subjects who were CYP3A5 expressers. CYP3A5 genotype
did not influence the R to S verapamil AUC ratio.
CONCLUSIONS: CYP3A5 expressers may experience dimin-
ished pharmacological effect of verapamil due to a greater steady-
state oral clearance in this group.
Table 1. Effect of CYP3A5 Expression on Verapamil Pharmacokinetics
Expressers
(N  10)
Non-expressors
(N10)
P
Value
R-verapamil
Cmax (ng/ml) 155.3  28.7 282.5  54.3 0.053
Cl/F (L/hour) 172.1  27.8 94.3  12.4 0.02
S-verapamil
Cmax (ng/ml) 32.2  6.9 67.2  16.1 0.061
Cl/F (L/hour) 925.1  162.7 473.7  81.5 0.02
AUC ratio
R/S Verapamil 5.3  0.3 4.7  0.3 0.21
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ESTROGEN RECEPTOR GENOTYPES ARE ASSOCIATED
WITH RESPONSE OF SERUM CHOLESTEROL TO TAMOX-
IFEN TREATMENT. N. I. Ntukidem, MD, L. Li, PhD, M. I. Reh-
man, MD, T. C. Skaar, PhD, Y. Jin, MD, Z. Desta, PhD, A. M.
Storniolo, MD, V. Stearns, MD, D. F. Hayes, MD, D. A. Flockhart,
MD, PhD, Indiana University, University of Michigan, Indianapolis,
IN.
BACKGROUND: Breast cancer and non-tumoral responses dur-
ing tamoxifen treatment are variable; and this variability may be
genetic.
METHODS: We prospectively followed 185 breast cancer pa-
tients on tamoxifen therapy. Serum lipid analyses were performed in
Clinical Laboratories at baseline and after 4 months of treatment.
Genetic variants in the estrogen receptors  [rs#2234693, (PvuII) and
rs#9340799 (XbaI)] and  [rs#1256049 (ESR2-01) and
rs#4986938(ESR-02)] were analyzed.
RESULTS: Tamoxifen significantly lowered cholesterol (24.2
mg/dl) and LDL (26.9mg/dl) compared to baseline. Women with
the ER PvuII CC allele had a 2-fold greater decrease in total choles-
terol when compared to women with CT/TT alleles (P0.01). The
premenopausal women with the AA/AG alleles of ER XbaI had a
lower baseline total (204 vs. 244 mg/dl; P0.012,) and LDL choles-
terol (116 vs.150mg/d; p0.0l) compared to women with the GG
alleles. There was no association between baseline cholesterol and
the XbaI polymorphism in postmenopausal women. In a multivariate
analysis, grouping the subjects according to their combined ER and
ER genotypes, the subgroup with ER  PvuII CC and any ESR2-02
allele combination had the greatest reduction in total cholesterol
concentration in response to tamoxifen when compared to women
with ER  CT/TT and any ESR2-02 (P0.0032).
CONCLUSIONS: Estrogen receptor genotypes are associated
with baseline cholesterol and the response of serum cholesterol to
tamoxifen treatment in breast cancer.
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